- Fund & Investor Interest
- Solebury Trout Updates
- Market Commentary
- IPO News
- Expert Interactions
- Conference Snippet
- Industry Snippets
- Solebury Trout Talks

IPO News: Filed S-1: NextCure Files $86.3mm IPO
NextCure
NextCure
NASDAQ: NXTC
Size (mm): $86.3
Bookrunners: MS | BAML | PJ
Major Holders: OrbiMed Private Investments | Canaan X L.P | Pfizer | Lilly Asia Ventures | HH NCure Holdings | Quan Venture Fund | Eli Lilly and Company
Description: NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.
Note: Emerging Growth Company
Reference Link: S-1